Emerging concepts of epigenetic dysregulation in hematological malignancies

Nature Immunology

Volumn 17, Issue 9, 2016, Pages 1016-1024

  Ntziachristos, Panagiotis ^a   Abdel Wahab, Omar ^b   Aifantis, Iannis ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEMETHYLASE; LONG UNTRANSLATED RNA; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PRC20 PROTEIN; UNCLASSIFIED DRUG; CHROMATIN; TRANSCRIPTOME;

CHROMATIN; CONFORMATION; DISEASE COURSE; DNA METHYLATION; ENHANCER REGION; EPIGENETICS; GENE MUTATION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LYMPHOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLICEOSOME; ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HIGH THROUGHPUT SEQUENCING; METABOLISM;

ANIMALS; CHROMATIN; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR CONFORMATION; RNA, LONG NONCODING; TRANSCRIPTOME;

EID: 84980390220     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3517     Document Type: Review

References (131)

1. Feinberg, A.P., Koldobskiy, M.A., & Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284-299 (2016
2. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013
3. Whyte, W.A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013
4. Heintzman, N.D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007
5. Gröschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157, 369-381 (2014
6. Yamazaki, H. et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21; q26) by activating EVI1 expression. Cancer Cell 25, 415-427 (2014
7. Mansour, M.R. et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373-1377 (2014
8. Puente, X.S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526, 519-524 (2015
9. Herranz, D. et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 20, 1130-1137 (2014
10. Wang, H. et al. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proc. Natl. Acad. Sci. USA 111, 705-710 (2014
11. Dekker, J., & Mirny, L. The 3D genome as moderator of chromosomal communication. Cell 164, 1110-1121 (2016
12. Dixon, J.R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376-380 (2012
13. Lieberman-Aiden, E. et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289-293 (2009
14. Bell, A.C., & Felsenfeld, G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405, 482-485 (2000
15. Hark, A.T. et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405, 486-489 (2000
16. Zuin, J. et al. Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc. Natl. Acad. Sci. USA 111, 996-1001 (2014
17. Trimarchi, T. et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell 158, 593-606 (2014
18. Keim, C., Kazadi, D., Rothschild, G., & Basu, U. Regulation of AID, the B-cell genome mutator. Genes Dev. 27, 1-17 (2013
19. Qian, J. et al. B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 159, 1524-1537 (2014
20. Meng, F.L. et al. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. Cell 159, 1538-1548 (2014
21. Zhang, Y. et al. Spatial organization of the mouse genome and its role in recurrent chromosomal translocations. Cell 148, 908-921 (2012
22. Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 4, 149ra118 (2012
23. Kon, A. et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232-1237 (2013
24. Thota, S. et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 124, 1790-1798 (2014
25. Mazumdar, C. et al. Leukemia-Associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell 17, 675-688 (2015
26. Mullenders, J. et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J. Exp. Med. 212, 1833-1850 (2015
27. Viny, A.D. et al. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J. Exp. Med. 212, 1819-1832 (2015
28. Watrin, E., Kaiser, F.J., & Wendt, K.S. Gene regulation and chromatin organization: relevance of cohesin mutations to human disease. Curr. Opin. Genet. Dev. 37, 59-66 (2016
29. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011
30. Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384-1395 (2011
31. Graubert, T.A. et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44, 53-57 (2011
32. Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497-2506 (2011
33. Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2011
34. Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617-630 (2015
35. Zhang, J. et al. Disease-Associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc. Natl. Acad. Sci. USA 112, E4726-E4734 (2015
36. Ilagan, J.O. et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14-26 (2014
37. Darman, R.B. et al. Cancer-Associated SF3B1 hotspot mutations induce cryptic 3? splice site selection through use of a different branch point. Cell Rep. 13, 1033-1045 (2015
38. Alsafadi, S. et al. Cancer-Associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016
39. Inoue, D., Bradley, R.K., & Abdel-Wahab Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev. 30, 989-1001 (2016
40. Daubner, G.M., Cléry, A., Jayne, S., Stevenin, J., & Allain, F.H. A syn-Anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J. 31, 162-174 (2012
41. Shirai, C.L. et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 27, 631-643 (2015
42. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616-3627, quiz 3699 (2013
43. Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241-247 (2014
44. Isono, K., Mizutani-Koseki, Y., Komori, T., Schmidt-Zachmann, M.S., & Koseki, H. Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. Genes Dev. 19, 536-541 (2005
45. Kfir, N. et al. SF3B1 association with chromatin determines splicing outcomes. Cell Rep. 11, 618-629 (2015
46. Garding, A. et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB. PLoS Genet. 9, e1003373 (2013
47. Stilgenbauer, S. et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 16, 1891-1897 (1998
48. Klein, U. et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40 (2010
49. Yildirim, E. et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152, 727-742 (2013
50. Luger, K., Mäder, A.W., Richmond, R.K., Sargent, D.F., & Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260 (1997
51. Kornberg, R.D. Chromatin structure: a repeating unit of histones and DNA. Science 184, 868-871 (1974
52. Tan, M. et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146, 1016-1028 (2011
53. Voigt, P., Tee, W.W., & Reinberg, D. A double take on bivalent promoters. Genes Dev. 27, 1318-1338 (2013
54. Bernstein, B.E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006
55. Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726 (2010
56. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010
57. Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013
58. McCabe, M.T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 109, 2989-2994 (2012
59. Sneeringer, C.J. et al. Coordinated activities of wild-Type plus mutant EZH2 drive tumor-Associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 107, 20980-20985 (2010
60. Yap, D.B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459 (2011
61. Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176-181 (2014
62. Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-301 (2012
63. Simon, C. et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26, 651-656 (2012
64. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012
65. Danis, E. et al. Ezh2 controls an early hematopoietic program and growth and survival signaling in early T cell precursor acute lymphoblastic leukemia. Cell Rep. 14, 1953-1965 (2016
66. Shi, J. et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9; Nras(G12D) acute myeloid leukemia. Oncogene 32, 930-938 (2013
67. Neff, T. et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 109, 5028-5033 (2012
68. Velichutina, I. et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116, 5247-5255 (2010
69. Chen, H. et al. Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev. 23, 975-985 (2009
70. Van Kruijsbergen, I., Hontelez, S., & Veenstra, G.J. Recruiting polycomb to chromatin. Int. J. Biochem. Cell Biol. 67, 177-187 (2015
71. Margueron, R., & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011
72. Gupta, R.A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071-1076 (2010
73. Shields, B.J. et al. Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a. Genes Dev. 30, 78-91 (2016
74. Lubitz, S., Glaser, S., Schaft, J., Stewart, A.F., & Anastassiadis, K. Increased apoptosis and skewed differentiation in mouse embryonic stem cells lacking the histone methyltransferase Mll2. Mol. Biol. Cell 18, 2356-2366 (2007
75. Wang, P. et al. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol. Cell. Biol. 29, 6074-6085 (2009
76. Shilatifard, A., Lane, W.S., Jackson, K.W., Conaway, R.C., & Conaway, J.W. An RNA polymerase II elongation factor encoded by the human ELL gene. Science 271, 1873-1876 (1996
77. Bernt, K.M., & Armstrong, S.A. A role for DOT1L in MLL-rearranged leukemias. Epigenomics 3, 667-670 (2011
78. Bernt, K.M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011
79. Tan, J. et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20, 563-575 (2011
80. Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953 (2004
81. Allis, C.D. et al. New nomenclature for chromatin-modifying enzymes. Cell 131, 633-636 (2007
82. Harris, W.J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012
83. Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-Trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat. Med. 18, 605-611 (2012
84. Yatim, A. et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol. Cell 48, 445-458 (2012
85. Li, Y. et al. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis. Oncogene 31, 5007-5018 (2012
86. Whetstine, J.R. et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125, 467-481 (2006
87. Agger, K. et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734 (2007
88. De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130, 1083-1094 (2007
89. Lan, F. et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 449, 689-694 (2007
90. Lee, M.G. et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318, 447-450 (2007
91. Jepsen, K. et al. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450, 415-419 (2007
92. Hong, S. et al. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 104, 18439-18444 (2007
93. Greenfield, A. et al. The UTX gene escapes X inactivation in mice and humans. Hum. Mol. Genet. 7, 737-742 (1998
94. Van der Meulen, J. et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 125, 13-21 (2015
95. Benyoucef, A. et al. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes Dev. 30, 508-521 (2016
96. Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014
97. Guo, J.U., Su, Y., Zhong, C., Ming, G.L., & Song, H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434 (2011
98. Ji, H. et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467, 338-342 (2010
99. Hogart, A. et al. Genome-wide DNA methylation profiles in hematopoietic stem and progenitor cells reveal overrepresentation of ETS transcription factor binding sites. Genome Res. 22, 1407-1418 (2012
100. Bock, C. et al. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol. Cell 47, 633-647 (2012
101. Figueroa, M.E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010
102. Ley, T.J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010
103. Smith, A.E. et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-Abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 116, 3923-3932 (2010
104. Mardis, E.R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009
105. Grossmann, V. et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosom. Cancer 52, 410-422 (2013
106. Shlush, L.I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014
107. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011
108. Li, Z. et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118, 4509-4518 (2011
109. An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat. Commun. 6, 10071 (2015
110. Lobry, C. et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J. Exp. Med. 210, 301-319 (2013
111. Shih, A.H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502-515 (2015
112. Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653-662 (2015
113. Ficz, G. et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473, 398-402 (2011
114. Pastor, W.A. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394-397 (2011
115. Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656-659 (2012
116. Chen, C. et al. Cancer-Associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 27, 1974-1985 (2013
117. Mayle, A. et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 125, 629-638 (2015
118. Meyer, S.E. et al. DNMT3A haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia. Cancer Discov. 6, 501-515 (2016
119. Chen, Q., Chen, Y., Bian, C., Fujiki, R., & Yu, X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493, 561-564 (2013
120. Vella, P. et al. Tet proteins connect the O-linked N-Acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol. Cell 49, 645-656 (2013
121. Flavahan, W.A. et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110-114 (2016
122. Bitler, B.G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231-238 (2015
123. Kim, K.H. et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med. 21, 1491-1496 (2015
124. McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492, 108-112 (2012
125. Knutson, S.K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012
126. Chen, C.W. et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat. Med. 21, 335-343 (2015
127. Daigle, S.R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011
128. Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622-626 (2013
129. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011
130. Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013
131. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011